Oric Pharmaceuticals Net Income Over Time
| ORIC Stock | USD 10.98 1.13 9.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oric Pharmaceuticals Performance and Oric Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Oric diversify its offerings? Factors like these will boost the valuation of Oric Pharmaceuticals. Anticipated expansion of Oric directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oric Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Oric Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oric's balance sheet. Smart investors calculate Oric Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Oric Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oric Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oric Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Oric Pharmaceuticals and related stocks such as Amylyx Pharmaceuticals, Relay Therapeutics, and Precigen Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (66.5 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (337.7 M) | (303.9 M) | (319.1 M) |
| PGEN | (85.3 M) | (85.3 M) | (81.9 M) | (39 M) | (81.8 M) | (84.5 M) | (186.6 M) | (117 M) | (509.3 M) | (170.5 M) | (170.5 M) | (92.2 M) | 28.3 M | (95.9 M) | (126.2 M) | (113.6 M) | (119.3 M) |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| INBX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (19.4 M) | (31.2 M) | (51.4 M) | (75.6 M) | (81.8 M) | (145.2 M) | (241.4 M) | 1.7 B | 1.9 B | 2 B |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (29.4 M) | (50.2 M) | (60.3 M) | (90.2 M) | (88.9 M) | (80 M) | (84 M) |
| ELVN | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (23.5 M) | (19 M) | (24.7 M) | (37.7 M) | (71.6 M) | (89 M) | (80.1 M) | (76.1 M) |
| ATAI | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (169.8 M) | (167.8 M) | (152.4 M) | (40.2 M) | (149.3 M) | (134.3 M) | (141.1 M) |
Oric Pharmaceuticals and related stocks such as Amylyx Pharmaceuticals, Relay Therapeutics, and Precigen Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Oric Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Oric Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Oric Pharmaceuticals | ORIC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 240 East Grand |
| Exchange | NASDAQ Exchange |
USD 10.98
Check out Oric Pharmaceuticals Performance and Oric Pharmaceuticals Correlation. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Oric Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.